Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study

Annals of Neurology

Volumn 68, Issue 6, 2010, Pages 963-968

  Weintraub, Daniel ^a,b   Sohr, Mandy ^c   Potenza, Marc N ^d,e   Siderowf, Andrew D ^a   Stacy, Mark ^f   Voon, Valerie ^g   Whetteckey, Jacqueline ^h   Wunderlich, Glen R ⁱ   Lang, Anthony E ^j  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f DUKE UNIVERSITY MEDICAL CENTER   (United States)

^g UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^h BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

ⁱ BOEHRINGER INGELHEIM CANADA LTD   (Canada)

^j UNIVERSITY OF TORONTO   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA;

ADULT; AGED; ARTICLE; BINGE EATING DISORDER; COMPULSIVE BUYING; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DRUG EFFECT; DRUG USE; FEMALE; HUMAN; HYPERSEXUALITY; IMPULSE CONTROL DISORDER; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PATHOLOGICAL GAMBLING; PRIORITY JOURNAL;

AGED; AMANTADINE; ANTIPARKINSON AGENTS; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; IMPULSE CONTROL DISORDERS; LOGISTIC MODELS; MALE; MIDDLE AGED; PARKINSON DISEASE;

EID: 78650864804     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.22164     Document Type: Article

References (20)

1. Weintraub D, Koester J, Potenza MN, et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol 2010; 67: 589-595.
2. Driver-Dunckley E, Samanta J, Stacy M,. Pathological gambling associated with dopamine agonist therapy in Parkinson's disease. Neurology 2003; 61: 422-423.
3. Dodd ML, Klos KJ, Bower JH, et al. Pathological gambling caused by drugs used to treat Parkinson disease. Arch Neurol 2005; 62: 1-5.
4. Mamikonyan E, Siderowf AD, Duda JE, et al. Long-term follow-up of impulse control disorders in Parkinson's disease. Mov Disord 2008; 23: 75-80.
5. Grant JE, Potenza MN,. Impulse control disorders: clinical characteristics and pharmacological management. Ann Clin Psychiatry 2004; 16: 27-34.
6. Grant JE, Potenza MN, Hollander E, et al. Multicenter investigation of the opioid antagonist nalmefene in the treatment of pathological gambling. Am J Psychiatry 2006; 163: 303-312.
7. Kim SW, Grant JE, Adson DE, et al. Double-blind naltrexone and placebo comparison study in the treatment of pathological gambling. Biol Psychiatry 2001; 49: 914-921.
8. Grant JE, Kim SW, Odlaug BL,. N-acetyl cysteine, a glutamate-modulating agent, in the treatment of pathological gambling: a pilot study. Biol Psychiatry 2007; 62: 652-657.
9. Thomas A, Iacono D, Luciano AL, et al. Duration of amantadine benefit on dyskinesia of severe Parkinson's disease. J Neurol Neurosurg Psychiatry 2004; 75: 141-143.
10. Thomas A, Bonnani L, Gambi F, et al. Pathological gambling in Parkinson disease is reduced by amantadine. Ann Neurol (in press). DOI:10.1002/ana.22029.
11. D-aspartate antagonism. Brain Res 1994; 662: 255-258.
12. Shaffer HJ, LaBrie R, Scanlan KM, et al. Pathological gambling among adolescents: Massachusetts gambling screen (MAGS). J Gambl Stud 1994; 10: 339-362.
13. Christenson GA, Faber RJ, deZwaan M,. Compulsive buying: descriptive characteristics and psychiatric comorbidity. J Clin Psychiatry 1994; 55: 5-11.
14. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. text revision. Washington, DC: American Psychiatric Association, 2000.
15. Evans AH, Katzenschlager R, Paviour D, et al. Punding in Parkinson's disease: its relation to the dopamine dysregulation syndrome. Mov Disord 2004; 19: 397-405.
16. Giovannoni G, O'Sullivan JD, Turner K, et al. Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry 2000; 68: 423-428.
17. Volonté MA, Moresco RM, Messa C, et al. A PET study with [11-C]raclopride in Parkinson's disease: preliminary results on the effect of amantadine on the dopaminergic system. Neurol Sci 2001; 22: 107-108.
18. Blanpied TA, Clarke RJ, Johnson JW,. Amantadine inhibits NMDA receptors by accelerating channel closure during channel block. J Neurosci 2005; 25: 3312-3322.
19. Weintraub D, Siderowf AD, Potenza MN, et al. Association of dopamine agonist use with impulse control disorders in Parkinson disease. Arch Neurol 2006; 63: 969-973.
20. Voon V, Fernagut P-O, Baunez C, et al. Chronic dopaminergic stimulation in Parkinson's disease: from dyskinesias to impulse control disorders. Lancet Neurol 2009; 8: 1140-1149.